207 related articles for article (PubMed ID: 24831239)
1. E2F inhibition synergizes with paclitaxel in lung cancer cell lines.
Kurtyka CA; Chen L; Cress WD
PLoS One; 2014; 9(5):e96357. PubMed ID: 24831239
[TBL] [Abstract][Full Text] [Related]
2. Silencing of X-linked inhibitor of apoptosis decreases resistance to cisplatin and paclitaxel but not gemcitabine in non-small cell lung cancer.
Liu Y; Wu X; Sun Y; Chen F
J Int Med Res; 2011; 39(5):1682-92. PubMed ID: 22117968
[TBL] [Abstract][Full Text] [Related]
3. Pre-clinical evaluation of new antineoplastic agents in NSCLC cell lines: evidence of histological subtype-dependent cytotoxicity.
Loprevite M; Favoni RE; de Cupis A; Pirani P; Merlo F; Grossi F; Ardizzoni A
Int J Oncol; 1999 Oct; 15(4):787-92. PubMed ID: 10493963
[TBL] [Abstract][Full Text] [Related]
4. Metuzumab enhanced chemosensitivity and apoptosis in non-small cell lung carcinoma.
Feng F; Wang B; Sun X; Zhu Y; Tang H; Nan G; Wang L; Wu B; Huhe M; Liu S; Diao T; Hou R; Zhang Y; Zhang Z
Cancer Biol Ther; 2017 Jan; 18(1):51-62. PubMed ID: 28055291
[TBL] [Abstract][Full Text] [Related]
5. Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells.
Sei S; Mussio JK; Yang QE; Nagashima K; Parchment RE; Coffey MC; Shoemaker RH; Tomaszewski JE
Mol Cancer; 2009 Jul; 8():47. PubMed ID: 19594950
[TBL] [Abstract][Full Text] [Related]
6. ErbB3 expression predicts sensitivity to elisidepsin treatment: in vitro synergism with cisplatin, paclitaxel and gemcitabine in lung, breast and colon cancer cell lines.
Teixidó C; Arguelaguet E; Pons B; Aracil M; Jimeno J; Somoza R; Marés R; Ramón Y Cajal S; Hernández-Losa J
Int J Oncol; 2012 Jul; 41(1):317-24. PubMed ID: 22485250
[TBL] [Abstract][Full Text] [Related]
7. Interactions of gemcitabine, carboplatin and paclitaxel in molecularly defined non-small-cell lung cancer cell lines.
Edelman MJ; Quam H; Mullins B
Cancer Chemother Pharmacol; 2001 Aug; 48(2):141-4. PubMed ID: 11561780
[TBL] [Abstract][Full Text] [Related]
8. Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer.
Fogli S; Danesi R; De Braud F; De Pas T; Curigliano G; Giovannetti G; Del Tacca M
Ann Oncol; 2001 Nov; 12(11):1553-9. PubMed ID: 11822754
[TBL] [Abstract][Full Text] [Related]
9. A small-molecule E2F inhibitor blocks growth in a melanoma culture model.
Ma Y; Kurtyka CA; Boyapalle S; Sung SS; Lawrence H; Guida W; Cress WD
Cancer Res; 2008 Aug; 68(15):6292-9. PubMed ID: 18676853
[TBL] [Abstract][Full Text] [Related]
10. A novel strategy of EGFR‑TKI combined chemotherapy in the treatment of human lung cancer with EGFR‑sensitive mutation.
Zhang L; Qi Y; Xing K; Qian S; Zhang P; Wu X
Oncol Rep; 2018 Aug; 40(2):1046-1054. PubMed ID: 29917169
[TBL] [Abstract][Full Text] [Related]
11. Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines.
Hirsch FR; Helfrich B; Franklin WA; Varella-Garcia M; Chan DC; Bunn PA
Clin Breast Cancer; 2002 May; 3 Suppl 1():12-6. PubMed ID: 12057039
[TBL] [Abstract][Full Text] [Related]
12. Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma.
Voigt W; Kegel T; Weiss M; Mueller T; Simon H; Schmoll HJ
J Cancer Res Clin Oncol; 2005 Sep; 131(9):585-90. PubMed ID: 16021466
[TBL] [Abstract][Full Text] [Related]
13. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents.
Bunn PA; Helfrich B; Soriano AF; Franklin WA; Varella-Garcia M; Hirsch FR; Baron A; Zeng C; Chan DC
Clin Cancer Res; 2001 Oct; 7(10):3239-50. PubMed ID: 11595720
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA‑433 reduces cell proliferation and invasion in non‑small cell lung cancer via directly targeting E2F transcription factor 3.
Liu N; Liu Z; Zhang W; Li Y; Cao J; Yang H; Li X
Mol Med Rep; 2018 Jul; 18(1):1155-1164. PubMed ID: 29767254
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells.
Ceresa C; Giovannetti E; Voortman J; Laan AC; Honeywell R; Giaccone G; Peters GJ
Mol Cancer Ther; 2009 May; 8(5):1026-36. PubMed ID: 19383850
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel alters the expression and specific activity of deoxycytidine kinase and cytidine deaminase in non-small cell lung cancer cell lines.
Shord SS; Patel SR
J Exp Clin Cancer Res; 2009 Jun; 28(1):76. PubMed ID: 19500405
[TBL] [Abstract][Full Text] [Related]
17. In vitro synergistic antitumor efficacy of sequentially combined chemotherapy/icotinib in non‑small cell lung cancer cell lines.
Wang MC; Liang X; Liu ZY; Cui J; Liu Y; Jing L; Jiang LL; Ma JQ; Han LL; Guo QQ; Yang CC; Wang J; Wu T; Nan KJ; Yao Y
Oncol Rep; 2015 Jan; 33(1):239-49. PubMed ID: 25370413
[TBL] [Abstract][Full Text] [Related]
18. The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells.
Oguri T; Achiwa H; Bessho Y; Muramatsu H; Maeda H; Niimi T; Sato S; Ueda R
Lung Cancer; 2005 Sep; 49(3):345-51. PubMed ID: 15993511
[TBL] [Abstract][Full Text] [Related]
19. Knockdown SNHG20 Suppresses Nonsmall Cell Lung Cancer Development by Repressing Proliferation, Migration and Invasion, and Inducing Apoptosis by Regulating miR-2467-3p/E2F3.
Chen H; Tan X; Ding Y
Cancer Biother Radiopharm; 2021 May; 36(4):360-370. PubMed ID: 32456448
[No Abstract] [Full Text] [Related]
20. Chemotherapy resistance and oncogene expression in non-small cell lung cancer.
d'Amato TA; Landreneau RJ; Ricketts W; Huang W; Parker R; Mechetner E; Yu IR; Luketich JD
J Thorac Cardiovasc Surg; 2007 Feb; 133(2):352-63. PubMed ID: 17258563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
